

IN THE CLAIMS:

Please cancel claims 4-6, 10-12, 17-23 and 27 without prejudice.

Please amend claims 1, 7, 13, 16, 24, 28 and 29 as follows:

1. (currently amended) A ~~substantially pure, isolated or recombinant~~ polypeptide which comprises:

- a) ~~comprises or consists of~~ the amino acid sequence ~~shown in figure 2b, of~~ SEQ ID NO: 2;
- b) an amino acid sequence is a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence ~~shown in figure 2b, of~~ SEQ ID NO: 2; or
- c) an amino acid sequence comprising is a fragment of a the polypeptide as defined in a) or b) above, which is at least ten amino acids long;

~~wherein the recombinant polypeptide and~~ comprises amino acids 73-86 of SEQ ID NO.: 2.

2. (original) A polypeptide as claimed in claim 1 which is provided as part of a fusion polypeptide.

3. (original) A polypeptide as claimed in claim 2 wherein the fusion polypeptide comprises Green Fluorescent Protein or the DsRed Fluorescent Protein.

4. (cancelled)

5. (cancelled)

6. (cancelled)

7. (currently amended) A ~~substantially pure, isolated or recombinant~~ polypeptide which comprises:

- a) ~~comprises or consists of~~ the amino acid sequence ~~shown in figure 3b (SEQ ID NO.: 4) of~~ SEQ ID NO: 4;
- b) an amino acid sequence is a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence ~~shown in figure 3b of~~ SEQ ID NO: 4; or

- c) an amino acid sequence comprising is a fragment of a the polypeptide as defined in a) or b) above, which is at least ten amino acids long;
~~wherein the polypeptide~~ and comprises amino acids 194 to 203 of SEQ ID NO.: 4.
8. (original) A polypeptide as claimed in claim 7 which is provided as part of a fusion polypeptide.
9. (original) A polypeptide as claimed in claim 8 wherein the fusion polypeptide comprises Green Fluorescent Protein or the DsRed Fluorescent Protein.
10. (cancelled)
11. (cancelled)
12. (cancelled)
13. (currently) A method of screening for and/or diagnosis of a neurological or neuropsychiatric condition in a subject, which method comprises the step of detecting and/or quantifying the amount of a polypeptide in a biological sample obtained from said subject, wherein the polypeptide is selected from:
- a) a polypeptide comprising the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4) of SEQ ID NO: 2;
 - b) a polypeptide comprising an amino acid sequence ~~a derivative~~ having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence ~~shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4) of~~ SEQ ID NO: 2; and
 - c) a polypeptide comprising an amino acid sequence comprising a fragment of a the polypeptide as defined in a) or b) above, which is at least ten amino acids long and comprises amino acids 73-86 of SEQ ID NO: 2;
 - d) a polypeptide comprising the amino acid sequence of SEQ ID NO: 4;
 - e) a polypeptide comprising an amino acid sequence having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID NO: 4; and

- f) a polypeptide comprising an amino acid sequence comprising a fragment of the polypeptide as defined in d) or e) above, which is at least ten amino acids long and comprises amino acids 194-203 of SEQ ID NO: 4.

14. (original) A method as claimed in claim 13, wherein the polypeptide is provided as part of a fusion polypeptide.

15. (original) A method as claimed in claim 14, wherein the fusion polypeptide is selected from the group consisting of Green Fluorescent Protein and DsRed Fluorescent Protein.

16. (currently amended) A method for the prophylaxis and/or treatment of a neurological or neuropsychiatric condition in a subject, which comprises administering to said subject a therapeutically effective amount of at least one polypeptide, wherein the polypeptide is selected from:

- a) a polypeptide comprising the amino acid sequence ~~shown in figures 2b or 3b~~ (SEQ ID NO: 2 or SEQ ID NO: 4) of SEQ ID NO: 2;
- b) a polypeptide comprising an amino acid sequence ~~a derivative~~ having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence ~~shown in figures 2b or 3b~~ (SEQ ID NO: 2 or SEQ ID NO: 4) of SEQ ID NO: 2; and
- c) a polypeptide comprising an amino acid sequence comprising a fragment of a the polypeptide as defined in a) or b) above, which is at least ten amino acids long and comprises amino acids 73-86 of SEQ ID NO: 2;
- d) a polypeptide comprising the amino acid sequence of SEQ ID NO: 4;
- e) a polypeptide comprising an amino acid sequence having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID NO: 4; and
- f) a polypeptide comprising an amino acid sequence comprising a fragment of a the polypeptide as defined in d) or e) above, which is at least ten amino acids long and comprises amino acids 194-203 of SEQ ID NO: 4.

17. (cancelled)

18. (cancelled)

19. (cancelled)

20. (cancelled)

21. (cancelled)

22. (cancelled)

23. (cancelled)

24. (currently amended) A pharmaceutical formulation comprising at least one polypeptide, wherein the polypeptide is selected from:

- a) a polypeptide comprising the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO: 4) of SEQ ID NO: 2;
- b) a polypeptide comprising an amino acid sequence a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO: 4) of SEQ ID NO: 2; and
- c) a polypeptide comprising an amino acid sequence comprising a fragment of a the polypeptide as defined in a) or b) above, which is at least ten amino acids long and comprises amino acids 73-86 of SEQ ID NO: 2;
- d) a polypeptide comprising the amino acid sequence of SEQ ID NO: 4;
- e) a polypeptide comprising an amino acid sequence having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID NO: 4; and
- f) a polypeptide comprising an amino acid sequence comprising a fragment of the polypeptide as defined in d) or e) above, which is at least ten amino acids long and comprises amino acids 194-203 of SEQ ID NO: 4;

~~at least one nucleic acid molecule wherein the nucleic acid molecule:~~

- ~~a) — comprises the DNA sequence shown in Figure 2a or 3a (SEQ ID NO: 1 or SEQ ID NO: 3), or its RNA equivalent;~~
- ~~b) — has a sequence which is complementary to the sequences of a);~~
- ~~c) — has a sequence which codes for the same polypeptide as the sequences of a) or b);~~

~~d) — has a sequence which shows substantial identity with any of those of a), b) and e); or~~
~~e) — has a sequence which codes for a derivative or fragment of an amino acid molecule shown in Figure 2a or 3a (SEQ ID NO.: 1 or SEQ ID NO.: 3);~~
~~or at least one antibody that binds to said polypeptide, optionally together with one or more pharmaceutically acceptable excipients, carriers or diluents.~~

25. (original) A pharmaceutical formulation as claimed in claim 24, wherein the pharmaceutical formulation is a vaccine.

26. (original) A pharmaceutical formulation as claimed in claim 25, which comprises one or more suitable adjuvants.

27. (cancelled)

28. (currently amended) A method of screening for compounds that modulate the expression of a polypeptide as defined in claims 1 or 7, which comprises the step of determining the presence or absence and/or quantifying at least one polypeptide as defined in claims 1 or 7 ~~or at least one antibody as defined in claim 19 or claim 20~~ in a biological sample.

29. (currently amended) A method for monitoring/assessing a neurological or neuropsychiatric condition treatment in a patient, which comprises the step of determining the presence or absence and/or quantifying at least one polypeptide as defined in claims 1 or 7 ~~or at least one antibody as defined in claim 19 or claim 20~~ in a biological sample obtained from said patient.